{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:23Z","timestamp":1787017103884,"version":"build-2736575974"},"reference-count":47,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/501100020484","name":"Foundation for Australia-Japan Studies","doi-asserted-by":"crossref","award":["FAJS2019"],"award-info":[{"award-number":["FAJS2019"]}],"id":[{"id":"10.13039\/501100020484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Cytogenetic abnormalities involving the\n                      <jats:italic>IGH<\/jats:italic>\n                      gene are seen in up to 55% of patients with multiple myeloma. Current testing is performed manually by fluorescence\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridisation (FISH) on purified plasma cells. We aimed to assess whether an automated imaging flow cytometric method that uses immunophenotypic cell identification, and does not require cell isolation, can identify\n                      <jats:italic>IGH<\/jats:italic>\n                      abnormalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Aspirated bone marrow from 10 patients with multiple myeloma were studied. Plasma cells were identified by CD38 and CD138 coexpression and assessed with FISH probes for numerical or structural abnormalities of\n                      <jats:italic>IGH<\/jats:italic>\n                      . Thousands of cells were acquired on an imaging flow cytometer and numerical data and digital images were analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Up to 30 000 cells were acquired and\n                      <jats:italic>IGH<\/jats:italic>\n                      chromosomal abnormalities were detected in 5 of the 10 marrow samples. FISH signal patterns seen included fused\n                      <jats:italic>IGH<\/jats:italic>\n                      signals for\n                      <jats:italic>IGH\/FGFR3<\/jats:italic>\n                      and\n                      <jats:italic>IGH\/MYEOV<\/jats:italic>\n                      , indicating t(4;14) and t(11;14), respectively. In addition, three\n                      <jats:italic>IGH<\/jats:italic>\n                      signals were identified, indicating trisomy 14 or translocation with an alternate chromosome. The lowest limit of detection of an\n                      <jats:italic>IGH<\/jats:italic>\n                      abnormality was in 0.05% of all cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This automated high-throughput immuno-flowFISH method was able to identify translocations and trisomy involving the\n                      <jats:italic>IGH<\/jats:italic>\n                      gene in plasma cells in multiple myeloma. Thousands of cells were analysed and without prior cell isolation. The inclusion of positive plasma cell identification based on immunophenotype led to a lowest detection level of 0.05% marrow cells. This imaging flow cytometric FISH method offers the prospect of increased precision of detection of critical genetic lesions involving\n                      <jats:italic>IGH<\/jats:italic>\n                      and other chromosomal defects in multiple myeloma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2022-208230","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T13:22:54Z","timestamp":1663334574000},"page":"763-769","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["<i>IGH<\/i>\n                    cytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry"],"prefix":"10.1136","volume":"76","author":[{"given":"Henry","family":"Hui","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, WA\nAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy A","family":"Fuller","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, WA\nAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Eresta Jaya","sequence":"additional","affiliation":[{"name":"Sysmex Corporation, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Konishi","sequence":"additional","affiliation":[{"name":"Sysmex Corporation, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Fong","family":"Ng","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, WA\nAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Frodsham","sequence":"additional","affiliation":[{"name":"Oxford Gene Technologies, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Speight","sequence":"additional","affiliation":[{"name":"Oxford Gene Technologies, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Sysmex Corporation, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Clarke","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, WA\nAustralia"},{"name":"PathWest Laboratory Medicine, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-9376","authenticated-orcid":false,"given":"Wendy N","family":"Erber","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, WA\nAustralia"},{"name":"PathWest Laboratory Medicine, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"2025092610155709000_76.11.763.1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2019004309","article-title":"Risk factors in multiple myeloma: is it time for a revision?","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"2025092610155709000_76.11.763.2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.seminoncol.2013.07.002","article-title":"Myeloma: classification and risk assessment","volume":"40","author":"Fonseca","year":"2013","journal-title":"Semin Oncol"},{"key":"2025092610155709000_76.11.763.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.07.009"},{"key":"2025092610155709000_76.11.763.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012"},{"key":"2025092610155709000_76.11.763.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00348-5"},{"key":"2025092610155709000_76.11.763.6","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"key":"2025092610155709000_76.11.763.7","doi-asserted-by":"publisher","DOI":"10.4065\/82.3.323"},{"key":"2025092610155709000_76.11.763.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"2025092610155709000_76.11.763.9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174"},{"key":"2025092610155709000_76.11.763.10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.beha.2005.01.006","article-title":"Genetics of multiple myeloma","volume":"18","author":"Higgins","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025092610155709000_76.11.763.11","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"2025092610155709000_76.11.763.12","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"key":"2025092610155709000_76.11.763.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"2025092610155709000_76.11.763.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257"},{"key":"2025092610155709000_76.11.763.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02324.x"},{"key":"2025092610155709000_76.11.763.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2025092610155709000_76.11.763.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00638-w","article-title":"Expressed fusion gene landscape and its impact in multiple myeloma","volume":"8","author":"Cleynen","year":"2017","journal-title":"Nat Commun"},{"key":"2025092610155709000_76.11.763.18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1365-2141.2003.04172.x","article-title":"Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results","volume":"120","author":"Harrison","year":"2003","journal-title":"Br J Haematol"},{"key":"2025092610155709000_76.11.763.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390658"},{"key":"2025092610155709000_76.11.763.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025092610155709000_76.11.763.21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000481523","article-title":"Comparison of IGH profile signals using t(4;14) and IGH break-apart probes by FISH in multiple myeloma","volume":"153","author":"Smol","year":"2017","journal-title":"Cytogenet Genome Res"},{"key":"2025092610155709000_76.11.763.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403340"},{"key":"2025092610155709000_76.11.763.23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/10245330512331389980","article-title":"Split-signal fish for detection of chromosome aberrations","volume":"10 Suppl 1","author":"van Dongen","year":"2005","journal-title":"Hematology"},{"key":"2025092610155709000_76.11.763.24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12805"},{"key":"2025092610155709000_76.11.763.25","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"2025092610155709000_76.11.763.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567370"},{"key":"2025092610155709000_76.11.763.27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.202200"},{"key":"2025092610155709000_76.11.763.28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41375-019-0634-2","article-title":"Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma","volume":"34","author":"Merz","year":"2020","journal-title":"Leukemia"},{"key":"2025092610155709000_76.11.763.29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2020","journal-title":"Virchows Arch"},{"key":"2025092610155709000_76.11.763.30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.321"},{"key":"2025092610155709000_76.11.763.31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051248","article-title":"The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025092610155709000_76.11.763.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0285-6","article-title":"Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and fish analysis","volume":"10","author":"Baril\u00e0","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025092610155709000_76.11.763.33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ajcp\/aqaa224","article-title":"Utility of flow cytometry and fluorescence in situ hybridization in follow-up monitoring of plasma cell myeloma","volume":"156","author":"Chopra","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"2025092610155709000_76.11.763.34","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPF7NFLW8UAJEP"},{"key":"2025092610155709000_76.11.763.35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056176"},{"key":"2025092610155709000_76.11.763.36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"2025092610155709000_76.11.763.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529800"},{"key":"2025092610155709000_76.11.763.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025092610155709000_76.11.763.39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-143323","article-title":"Detection of Del(17p) in hematological malignancies by imaging flow cytometry","volume":"136","author":"Erber","year":"2020","journal-title":"Blood"},{"key":"2025092610155709000_76.11.763.40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymeth.2017.11.003","article-title":"Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia","volume":"134-135","author":"Hui","year":"2018","journal-title":"Methods"},{"key":"2025092610155709000_76.11.763.41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cyto.a.23769","article-title":"\"Immuno-flowFISH\" for the assessment of cytogenetic abnormalities in chronic lymphocytic leukemia","volume":"95","author":"Hui","year":"2019","journal-title":"Cytometry A"},{"key":"2025092610155709000_76.11.763.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187440","article-title":"Optimizing recovery of frozen human peripheral blood mononuclear cells for flow cytometry","volume":"12","author":"H\u00f8nge","year":"2017","journal-title":"PLoS One"},{"key":"2025092610155709000_76.11.763.43","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.260","article-title":"Multi-probe fish analysis of immunophenotyped chronic lymphocytic leukemia by imaging flow cytometry","volume":"1","author":"Hui","year":"2021","journal-title":"Curr Protoc"},{"key":"2025092610155709000_76.11.763.44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cyto.a.22852","article-title":"Development of a robust immuno-S-FISH protocol using imaging flow cytometry","volume":"89","author":"Fuller","year":"2016","journal-title":"Cytometry A"},{"key":"2025092610155709000_76.11.763.45","first-page":"S0031","article-title":"Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma","volume":"33","author":"Lam","year":"2022","journal-title":"Pathology"},{"key":"2025092610155709000_76.11.763.46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/cyto.a.22101","article-title":"Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension","volume":"81","author":"Minderman","year":"2012","journal-title":"Cytometry A"},{"key":"2025092610155709000_76.11.763.47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41578-020-0180-6","article-title":"Automated molecular-image cytometry and analysis in modern oncology","volume":"5","author":"Weissleder","year":"2020","journal-title":"Nat Rev Mater"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:16:06Z","timestamp":1758906966000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/jcp-2022-208230"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208230","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}